Literature DB >> 25894736

Identification of epithelial ovarian tumor-specific aptamers.

Gregory Benedetto1, Timothy J Hamp1,2, Peter J Wesselman1, Christine Richardson1.   

Abstract

Ovarian cancer is often diagnosed in late stages with few treatment options and poor long-term prognosis. New clinical tools for early detection of ovarian malignancies will significantly help reduce mortality and improve current long-term survival rates. The objective of this work was to identify ovarian tumor-specific single-stranded DNA aptamers that bind to malignant ovarian tumor cells and internalize with high affinity and specificity. Aptamers can identify unique tumor biomarkers, can aid in early detection and diagnosis of neoplastic disorders, and can be functionalized by conjugation to small molecules. To identify aptamers from random single-stranded DNA pools (60 bases long), we used whole Cell-SELEX (systematic evolution of ligands by exponential enrichment) to enrich and isolate tumor-specific aptamers that bind to tumor-specific receptors in their native state on the cell surface. Next-Generation sequencing identified seven novel aptamers and detailed analyses of three are described. Aptamers bound to, and were internalized by, target Caov-3 cell populations, but not nontarget nonmalignant ovarian epithelial HOSE 6-3 cells or multiple other epithelial tumor cell lines. Furthermore, aptamers showed unique binding affinities with apparent dissociation constants (Kd) measuring in the submicromolar range supporting their physiological relevance and potential use in clinical applications.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25894736      PMCID: PMC4440997          DOI: 10.1089/nat.2014.0522

Source DB:  PubMed          Journal:  Nucleic Acid Ther        ISSN: 2159-3337            Impact factor:   5.486


  48 in total

1.  A cell-based single-stranded DNA aptamer specifically targets gastric cancer.

Authors:  Xiaojiao Zhang; Jun Zhang; Yanyun Ma; Xiaoyu Pei; Qingmei Liu; Bin Lu; Li Jin; Jiucun Wang; Jie Liu
Journal:  Int J Biochem Cell Biol       Date:  2014-01       Impact factor: 5.085

Review 2.  Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases.

Authors:  Eugene W M Ng; Anthony P Adamis
Journal:  Ann N Y Acad Sci       Date:  2006-10       Impact factor: 5.691

3.  A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer.

Authors:  I Jacobs; D Oram; J Fairbanks; J Turner; C Frost; J G Grudzinskas
Journal:  Br J Obstet Gynaecol       Date:  1990-10

4.  Derivation of RNA aptamer inhibitors of human complement C5.

Authors:  G Biesecker; L Dihel; K Enney; R A Bendele
Journal:  Immunopharmacology       Date:  1999-05

5.  A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.

Authors:  Richard G Moore; D Scott McMeekin; Amy K Brown; Paul DiSilvestro; M Craig Miller; W Jeffrey Allard; Walter Gajewski; Robert Kurman; Robert C Bast; Steven J Skates
Journal:  Gynecol Oncol       Date:  2008-10-12       Impact factor: 5.482

6.  The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells.

Authors:  Sridharan Soundararajan; Weiwei Chen; Eleanor K Spicer; Nigel Courtenay-Luck; Daniel J Fernandes
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

7.  Study of the molecular recognition of aptamers selected through ovarian cancer cell-SELEX.

Authors:  Dimitri Van Simaeys; Dalia López-Colón; Kwame Sefah; Rebecca Sutphen; Elizabeth Jimenez; Weihong Tan
Journal:  PLoS One       Date:  2010-11-01       Impact factor: 3.240

8.  Conditional survival in ovarian cancer: results from the SEER dataset 1988-2001.

Authors:  Mehee Choi; Clifton D Fuller; Charles R Thomas; Samuel J Wang
Journal:  Gynecol Oncol       Date:  2008-03-07       Impact factor: 5.482

Review 9.  Ovarian epithelial cancer stem cells.

Authors:  Irena Conic; Irena Dimov; Desanka Tasic-Dimov; Biljana Djordjevic; Vladisav Stefanovic
Journal:  ScientificWorldJournal       Date:  2011-06-09

10.  Targeting Axl with an high-affinity inhibitory aptamer.

Authors:  Laura Cerchia; Carla L Esposito; Simona Camorani; Anna Rienzo; Loredana Stasio; Luigi Insabato; Andrea Affuso; Vittorio de Franciscis
Journal:  Mol Ther       Date:  2012-08-21       Impact factor: 11.454

View more
  5 in total

1.  Selection and Identification of Skeletal-Muscle-Targeted RNA Aptamers.

Authors:  Styliana Philippou; Nikolaos P Mastroyiannopoulos; Neoklis Makrides; Carsten W Lederer; Marina Kleanthous; Leonidas A Phylactou
Journal:  Mol Ther Nucleic Acids       Date:  2017-12-09       Impact factor: 8.886

Review 2.  Aptamers: novelty tools for cancer biology.

Authors:  Ricardo L Pereira; Isis C Nascimento; Ana P Santos; Isabella E Y Ogusuku; Claudiana Lameu; Günter Mayer; Henning Ulrich
Journal:  Oncotarget       Date:  2018-06-01

Review 3.  Aptamer Nanomaterials for Ovarian Cancer Target Theranostics.

Authors:  Jing Zhao; Wenxi Tan; Jingying Zheng; Yuanzhen Su; Manhua Cui
Journal:  Front Bioeng Biotechnol       Date:  2022-03-28

Review 4.  Generating Cell Targeting Aptamers for Nanotheranostics Using Cell-SELEX.

Authors:  Yifan Lyu; Guang Chen; Dihua Shangguan; Liqin Zhang; Shuo Wan; Yuan Wu; Hui Zhang; Lian Duan; Chao Liu; Mingxu You; Jie Wang; Weihong Tan
Journal:  Theranostics       Date:  2016-06-15       Impact factor: 11.556

Review 5.  The Potential of Aptamer-Mediated Liquid Biopsy for Early Detection of Cancer.

Authors:  Dhruvajyoti Roy; Andreas Pascher; Mazen A Juratli; Judith C Sporn
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.